Interleukin-10, interleukin-6 and interferon-γ gene polymorphisms in melanoma patients
Interleukin-10, interleukin-6 and interferon-γ gene polymorphisms in melanoma patients
复制标题
DOI：
10.1097/00008390-200209000-00008
复制
发表时间：
2002-09-01
影响因子：
2.2
通讯作者：
Alvarez-López, MR
中科院分区：
文献类型：
--
作者：
Martínez-Escribano, JA;Moya-Quiles, MR;Alvarez-López, MR
针对黑色素瘤的免疫应答可受到对肿瘤细胞生长具有潜在相反作用的细胞因子的影响，例如白细胞介素-10（IL-10）、白细胞介素-6（IL-6）和干扰素-γ（IFN-γ）。本研究的目的是探讨IL 10、IL 6和IFN γ基因调控区的多态性是否与原发性皮肤黑色素瘤的发生和/或该肿瘤的预后相关。我们研究了42名黑色素瘤患者和48名健康对照中IL 10启动子-1082、-819和-592、IL 6启动子-174和IFN γ内含子1 +874位点的基因型变异。这两个群体显示出非常相似的基因型频率IL 10，IL 6和IFN γ基因多态性。在预后较差的患者中，IL 10低表达基因型的患病率显著增加，特别是ACC/ATA基因型。相反，IL 6启动子和IFN γ内含子1基因多态性与黑色素瘤预后无关。这些数据表明，在IL 10，IL 6和INF γ基因的调控区的多态性的调查似乎并不适用于预测原发性皮肤黑色素瘤的发展风险。然而，IL 10低表达基因型可能与黑色素瘤患者的预后较差相关。(C)2002年利平科特威廉姆斯威尔金斯。
The immune response against melanoma can be influenced by cytokines with potentially opposite effects on tumour cell growth, such as interieukin-10 (IL10), interieukin-6 (IL-6) and interferon-gamma (IFNgamma). Our objective in this study was to investigate whether polymorphisms in the regulatory regions of IL10, IL6 and IFNgamma genes are associated with the development of primary cutaneous melanoma and/or the prognosis of this tumour. We studied genotypic variations at positions -1082, -819 and -592 in the IL10 promoter, -174 in the IL6 promoter and +874 in the IFNgamma intron 1 in 42 melanoma patients and 48 healthy controls. These two populations showed very similar genotypic frequencies for IL10, IL6 and IFNgamma gene polymorphisms. There was a significant increase in the prevalence of IL10 low expression genotypes, specially the ACC/ATA genotype, among patients with a poorer prognosis. In contrast, IL6 promoter and IFNgamma intron 1 gene polymorphisms did not correlate with melanoma prognosis. These data indicate that investigation of polymorphisms in the regulatory regions of IL10, IL6 and INFgamma genes does not seem to be useful for predicting the risk of development of primary cutaneous melanoma. However, IL10 low expression genotypes may be associated with a poorer outcome in melanoma patients. (C) 2002 Lippincott Williams Wilkins.